Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial
Official title:
Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02964273 -
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
|
Phase 3 | |
| Terminated |
NCT01223755 -
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
|
Phase 2/Phase 3 | |
| Completed |
NCT01280721 -
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
|
Phase 3 | |
| Completed |
NCT02225860 -
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01616927 -
Study of Lanreotide to Treat Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01430494 -
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT00346918 -
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT03949894 -
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT02925221 -
Canadian Medical Assessment of JINARC™ Outcomes Registry
|
||
| Completed |
NCT04689074 -
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
|
||
| Terminated |
NCT02616055 -
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
|
Phase 2 | |
| Recruiting |
NCT06289998 -
Study of Tamibarotene in Patients With ADPKD
|
Phase 2 | |
| Completed |
NCT02112136 -
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD
|
N/A | |
| Recruiting |
NCT02115659 -
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT00309283 -
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
|
Phase 3 | |
| Recruiting |
NCT06345755 -
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants
|
Phase 1 |